Lifeboat Foundation

The Higgs boson is an elementary particle in the Standard Model of particle physics, produced by the quantum excitation of the Higgs field,^[8][9] one of the fields in particle physics theory.^[9] It is named after physicist Peter Higgs, who in 1964, along with five other scientists, proposed the Higgs mechanism to explain why particles have mass. This mechanism implies the existence of the Higgs boson. The boson’s existence was confirmed in 2012 by the ATLAS and CMS collaborations based on collisions in the LHC at CERN.

On December 10, 2013, two of the physicists, Peter Higgs and François Englert, were awarded the Nobel Prize in Physics for their theoretical predictions. Although Higgs’s name has come to be associated with this theory (the Higgs mechanism), several researchers between about 1960 and 1972 independently developed different parts of it.

In mainstream media the Higgs boson has often been called the “God particle”, from a 1993 book on the topic,^[10] although the nickname is strongly disliked by many physicists, including Higgs himself, who regard it as sensationalism.^[11][12].

Spraying this material on desert sand will turn it into green, fertile land.

NaNotics, in another breakthrough, is promising a new kind of medication, and suggests to have found a way to combat age related diseases; boldly going where no nanotech has gone before.

Lou Hawthorne of NaNotics, LLC opened his presentation at a recent longevity investor event using a clip from Star Trek that shows captain Kirk being giving a shot that restores him to his younger years.

“It’s tempting to assume it’s a drug, but what if the content of that syringe was something new?” NaNotics’ CEO Hawthorne asked. “NaNots are a new class of medicine. They are engineered to do just one thing and that’s the holy grail of medicine design, because most drugs do two things: something you want them to do, and something you don’t. In other words, side effects.”

Excerpt of Brent Nally’s interview to Dr. Michael Fossel about his company Telocyte and telomerase gene therapy. The interview took place on November 16, 2019.

To watch the entire three and a half hour enlightening interview click here:

Continue reading “Michael Fossel on activating Telomerase as best single antiaging intervention” »

The relationship between health and the microorganisms living in the gut has increasingly reached the spotlight in the last few years, and a new study led by researchers at Nanyang Technological University, Singapore (NTU Singapore) sheds more light on the gut microbiome and how it can influence aging.

The gut microbiome

Continue reading “Gut Microbes Support Neurogenesis and Longevity Hormone Production” »

ERCC1 (excision repair cross complementing‐group 1) is a mammalian endonuclease that incises the damaged strand of DNA during nucleotide excision repair and interstrand cross‐link repair. Ercc1^−/Δ mice, carrying one null and one hypomorphic Ercc1 allele, have been widely used to study aging due to accelerated aging phenotypes in numerous organs and their shortened lifespan. Ercc1^−/Δ mice display combined features of human progeroid and cancer‐prone syndromes. Although several studies report cellular senescence and apoptosis associated with the premature aging of Ercc1^−/Δ mice, the link between these two processes and their physiological relevance in the phenotypes of Ercc1^−/Δ mice are incompletely understood. Here, we show that ERCC1 depletion, both in cultured human fibroblasts and the skin of Ercc1^−/Δ mice, initially induces cellular senescence and, importantly, increased expression of several SASP (senescence‐associated secretory phenotype) factors. Cellular senescence induced by ERCC1 deficiency was dependent on activity of the p53 tumor‐suppressor protein. In turn, TNFα secreted by senescent cells induced apoptosis, not only in neighboring ERCC1‐deficient nonsenescent cells, but also cell autonomously in the senescent cells themselves. In addition, expression of the stem cell markers p63 and Lgr6 was significantly decreased in Ercc1^−/Δ mouse skin, where the apoptotic cells are localized, compared to age‐matched wild‐type skin, possibly due to the apoptosis of stem cells. These data suggest that ERCC1‐depleted cells become susceptible to apoptosis via TNFα secreted from neighboring senescent cells. We speculate that parts of the premature aging phenotypes and shortened health‐ or lifespan may be due to stem cell depletion through apoptosis promoted by senescent cells.

Investing in the age of longevity, london.

14 Nov 2019

Last week, the transhumanist activist Zoltan Istvan announced his candidacy for President of the United States in next year’s elections. The writer, humanitarian and outspoken advocate of radical science is no stranger to the issues surrounding Longevity, and has spoken widely on subjects including AI, genetic editing, technology policy, and futurism.

In 2016, Istvan ran as an independent presidential candidate and travelled across the United States, spreading his message from a coffin-shaped bus, known as the “Immortality Bus.” This time he’s on the ballot, running against Donald Trump as a candidate for the Republican party in next year’s primaries. Things are a bit more serious this time.

Among his key policies, Istvan includes transhumanism, universal basic income and the need to beat China in the global innovation race – an issue we addressed in our Jamie Metzl interview. We spoke to him to find out more about his views on the Longevity sector.

A team from Cincinnati Children’s Hospital tracked stem cells injected into the hearts of mice, and what they found could explain why clinical trials testing stem cell therapies in people with heart disease have been unsuccessful. They believe a smarter approach could be to harness the power of macrophages that provide healing in response to inflammation.